The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies

被引：15
|
作者：
Ueda, Kosuke [1 ]
Ogasawara, Naoyuki [1 ]
Yonekura, Satoru [2 ]
Matsunaga, Yoshihiro [1 ]
Hoshino, Ryuji [1 ]
Kurose, Hirofumi [1 ]
Chikui, Katsuaki [1 ]
Uemura, Keiichiro [1 ]
Nakiri, Makoto [1 ]
Nishihara, Kiyoaki [1 ]
Matsuo, Mitsunori [1 ]
Suekane, Shigetaka [1 ]
Igawa, Tsukasa [1 ]
机构：
[1] Kurume Univ, Sch Med, Dept Urol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Gustave Roussy Canc Campus, Villejuif, France
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 03期
关键词：
Renal cell carcinoma; molecular targeted therapy; inflammatory marker; C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; PROTEIN/ALBUMIN RATIO; LYMPHOCYTE RATIO; CANCER; NEUTROPHIL; OUTCOMES; LEVEL; NLR;
D O I：
10.21873/anticanres.14127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: The present study examined the impact of systemic inflammatory markers including Creactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. Patients and Methods: A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed. Results: High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, prior nephrectomy (p=0.0013) and CRP/Alb ratio (p= 0.0020) were independent prognostic factors for OS. Conclusion: CRP/Alb and NLR/Alb ratios are useful and independent prognostic biomarkers in patients with advanced RCC treated with molecular targeted therapy.
引用
收藏
页码：1739 / 1745
页数：7
相关论文
共 50 条
  • [1] Prognostic markers and targeted therapies for renal cell carcinoma
    Gimenez, S. Elena
    Secasan, Ciprian
    Raman, Jay D.
    FUTURE ONCOLOGY, 2009, 5 (02) : 197 - 205
  • [2] Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma
    Nouhaud, F. X.
    Rebibo, J. -D.
    Blanchard, F.
    Sabourin, J. -C.
    Di Fiore, F.
    Pfister, C.
    PROGRES EN UROLOGIE, 2014, 24 (09): : 563 - 571
  • [3] Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
    G Procopio
    E Verzoni
    R Iacovelli
    D Biasoni
    I Testa
    L Porcu
    F De Braud
    British Journal of Cancer, 2012, 107 : 1227 - 1232
  • [4] Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
    Procopio, G.
    Verzoni, E.
    Iacovelli, R.
    Biasoni, D.
    Testa, I.
    Porcu, L.
    De Braud, F.
    BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1227 - 1232
  • [5] Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
    Conti, Alessandro
    Santoni, Matteo
    Amantini, Consuelo
    Burattini, Luciano
    Berardi, Rossana
    Santoni, Giorgio
    Cascinu, Stefano
    Muzzonigro, Giovanni
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [6] Prognostic Value of Systemic Inflammatory Markers in Patients With Hepatocellular Carcinoma
    Muhanna, Adel
    Mansour, Razan
    Amarin, Justin
    Al-Hussaini, Maysa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S533 - S533
  • [7] Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma
    Marta, Guilherme Nader
    Velho, Pedro Isaacsson
    Bonadio, Renata R. C.
    Nardo, Mirella
    Faraj, Sheila F.
    de Azevedo Souza, Manoel Carlos L.
    Muniz, David Q. B.
    Bastos, Diogo Assed
    Dzik, Carlos
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2489 - 2497
  • [8] Prognostic significance of the mechanism of inflammatory markers in advanced renal cell carcinoma patients treated with nivolumab plus ipilimumab
    Nakayama, T.
    Takeshita, H.
    Kagawa, M.
    Washino, S.
    Shirotake, S.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Inoue, M.
    Miyagawa, T.
    Oyama, M.
    Saito, K.
    Kageyama, Y.
    Kawakami, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1487 - S1487
  • [9] Three-Dimensional Choi Response Criteria in Patients with Advanced Renal Cell Carcinoma Treated with Molecular Targeted Therapies
    Kensuke, S.
    Obara, W.
    Fujioka, T.
    Sone, M.
    Ehara, S.
    UROLOGY, 2012, 80 (03) : S92 - S92
  • [10] Molecular profiles and response among metastatic renal cell carcinoma patients treated with targeted therapies
    Donskov, F.
    Pinto, C. A.
    Predoui, R.
    Kong, F.
    Fox, C.
    Georgsen, J.
    Skaarup, K.
    Perini, R.
    Steiniche, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S301 - S301
12345